The present disclosure provides a method of treating a solid tumor cancer. The method includes administering a combination to a subject in need thereof. The combination includes at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The present disclosure also provides an anti-tumor agent for use in a method of treating cancer. In such instances, the anti-tumor agent may include the combination.

Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a heterologous antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the heterologous antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat a proliferative disease in a subject in need thereof.

Provided are modified bacteria and derivatives thereof that express antigens of interest. In some embodiments, the bacterium has a reduced genome and induces an enhanced immune response against the antigen of interest when administered to a subject as compared to an immune response that would have been induced by a bacterium of the same strain that has a full complement of genes. In some embodiments, the antigen is expressed on a surface of a bacterium. Also provided are method for producing antibody against antigens of interest, vaccine compositions, methods for vaccinating subjects, methods for treating cancers in subjects, methods for modulating inappropriate and undesirable immune response, methods for targeting materials in or on a human or animal that may be the cause of disease or otherwise undesirable phenotypes, and expression vectors for expressing antigens on the surface of reduced genome bacteria.

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.

Microorganisms are provided, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a CeD-specific antigen (e.g., a gliadin polypeptide comprising at least one HLA-DQ2 specific epitope, at least one deamidated HLA-DQ2 specific epitope, at least one HLA-DQ8 specific epitope, at least one deamidated HLA-DQ8 specific epitope, or a combination of (a) at least one HLA-DQ2-specific epitope and/or at least one deamidated HLA-DQ2 specific epitope, and (b) at least one HLA-DQ8 specific epitope and/or at least one deamidated HLA-DQ8 specific epitope) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. Compositions (e.g., pharmaceutical compositions), methods of using the microorganisms and compositions are provided, e.g., for the treatment of celiac disease (CeD). The microorganism may be administered orally, delivering the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides.

This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.

Recombinant BCG, a preparation method therefor and an application thereof. A shuttle plasmid that can express a FimH protein on the surface of BCG is constructed, and a gene fragment that expresses the FimH protein is transformed into wild-type BCG to thereby obtain recombinant BCG. Upon verification, the recombinant BCG can express the FimH protein on the surface of BCG; therefore, the BCG can specifically bind to subjects that can selectively bind to the FimH protein. The recombinant BCG can also enhance the local innate immune effect and adaptive immune effect induced by BCG and the anti-tumor effect of peripheral blood mononuclear cells, and also significantly improves the effect of BCG against bladder tumors, and is used to treat bladder tumors.

Disclosed in the present invention is a Helicobacter pylori ferritin-based novel coronavirus S protein double-region subunit nanovaccine. According to the present invention, both a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are taken as double antigens and are connected with a Helicobacter pylori multimeric protein (HP_Ferritin) to form a fusion protein RBD-FP-HP_Ferritin, so that antigen multimerization is realized; and an eukaryotic cell expression system is then utilized for expression, so as to form a 24-mer nano-antigen by means of the self-assembly action of the HP_Ferritin. According to the solution, the defect that RBD monomers are insufficient in immunogenicity can be overcome; the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses; and the generated antibodies have the capacity to strongly prevent the viruses from invading target cells.

The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.